Loading...
Please wait, while we are loading the content...
Similar Documents
The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.
| Content Provider | Europe PMC |
|---|---|
| Author | Di Marco, Fabiano D’Amato, Mariella Lombardo, Francesco P. Micheletto, Claudio Heiman, Franca Pegoraro, Valeria Boarino, Silvia Manna, Giandomenico Mastromauro, Francesca Spennato, Simona Papi, Alberto |
| Abstract | IntroductionPreliminary results from the SABINA (SABA use IN Asthma) program showed lower overuse of short-acting β2-agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA’s results might have been affected by the Italian National Health System and pharmaceutical market dynamics, by examining patients’ characteristics in relation to SABA prescription/purchase habits.MethodsMultiple approaches were used: (1) a retrospective study using the General Practitioners’ (GPs) Italian IQVIA Longitudinal Patient Database (LPD) to assess SABA overuse (more than two canisters/year) and its association with exacerbation risk; (2) a survey conducted across 200 Italian pharmacies to calculate the proportions of SABA purchases without a prescription; (3) a cross-sectional study on the specialists’ IQVIA Patient Analyzer database to understand the SABA prescription habits of specialists.ResultsAmong SABA users identified through IQVIA LPD, the proportion of patients having more than two SABA canisters/year was 32%. Overall, patients prescribed more than two SABA canisters/year by GPs had 30% higher risk of exacerbations than patients with a maximum of two SABA canisters/year. The joint evaluation of IQVIA LPD and survey’s findings revealed that IQVIA LPD tracks three out of four SABA canisters dispensed. The survey showed that, on average, SABA users purchased four canisters/year. Patients prescribed SABA by specialists were more frequently men, younger, thinner, and had higher spirometry values.ConclusionSABA overuse is common in Italy, with a share of consumption not regulated by medical prescriptions. Because SABA overuse increases exacerbation risk, changes to national guidelines should be encouraged to ensure implementation of global recommendations.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12325-021-01772-0. |
| ISSN | 0741238X |
| Journal | Advances in Therapy |
| Volume Number | 38 |
| PubMed Central reference number | PMC8280008 |
| Issue Number | 7 |
| PubMed reference number | 34043208 |
| e-ISSN | 18658652 |
| DOI | 10.1007/s12325-021-01772-0 |
| Language | English |
| Publisher | Springer Healthcare |
| Publisher Date | 2021-05-27 |
| Publisher Place | Cheshire |
| Access Restriction | Open |
| Rights License | Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. © The Author(s) 2021 |
| Subject Keyword | Asthma SABA consumption Guideline recommendations Exacerbations Primary care Real-world evidence |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) |
